Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.
Follow EBS
Emergent Biosolutions Inc. (EBS) EV/Sales
As of 16 October 2026, Emergent Biosolutions Inc. (EBS) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.8× (April 2025) to 6.1× (August 2020); the current reading is higher than 16% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 35.13% |
| FY2024 | 1.0× | 21.60% |
| FY2023 | 0.8× | (31.27%) |
| FY2022 | 1.2× | (16.34%) |
| FY2021 | 1.5× | (54.39%) |
| FY2020 | 3.2× | 3.50% |
| FY2019 | 3.1× | (33.72%) |
| FY2018 | 4.7× | 42.15% |
| FY2017 | 3.3× | 22.07% |
| FY2016 | 2.7× | (11.37%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | (8.96%) |
| Mar 2026 | 1.2× | (9.65%) |
| Dec 2025 | 1.4× | 23.14% |
| Sep 2025 | 1.1× | 28.37% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)